The means of optimally managing very elderly patients with diffuse large B-cell lymphoma (DLBCL) has not been established. We retrospectively analyzed 252 patients aged 80-100 years, diagnosed with DLBCL or grade 3B follicular lymphoma, treated in 19 hospitals from the GELTAMO group.
| I N TR ODU C TI ON
Diffuse large B-cell lymphoma (DLBCL) is the most commonly diagnosed non-Hodgkin lymphoma in Western countries. 1 It is also a disease of the elderly, with a median age at diagnosis of 70 years, 2 and almost onethird of newly diagnosed patients are over the age of 75 years. 3 While DLBCL is a potentially curable malignancy, evidence suggests that elderly patients do worse than their younger counterparts. 4 These inferior outcomes may reflect undertreatment resulting from hematologists' perception that elderly patients are unable to tolerate aggressive therapy 1 . In addition, older individuals often have a variety of comorbidities that may preclude administration of effective therapies at the appropriate dose intensity. 5 Conversely, DLBCL in elderly patients may be biologically and molecularly different from DLBCL in younger patients. 6 These observations have minimized the participation of elderly patients in clinical trials, especially those over 80 years, and treatment strategies are often based on results from studies conducted with younger, relatively fit patients, or on retrospective analysis that are often limited by the sample size. 1, [7] [8] [9] Although there is some evidence
suggesting that R-CHOP should be used in this age group, [8] [9] [10] [11] [12] other studies have shown that full-dose chemotherapy may be associated with poorer survival because of excess toxicities. 9, 13, 14 In the present study, we have retrospectively analyzed the clinical characteristics and outcomes of a large series of patients with DLBCL who were older than 80 years and treated in 19 member hospitals of the GELTAMO group. Specifically, we investigated factors associated with treatment selection and examined the impact of the type of treatment and comorbidities on survival.
| M E TH ODS

| Study design and patients
Nineteen GELTAMO centers participated in this retrospective study.
Investigators from each center were required to report all patients who met the following inclusion criteria: (1) 
| Assessment of comorbidities
Comorbidities, defined as chronic medical conditions that can affect patient life span, were assessed retrospectively using the following methods:
1. Cumulative illness rating scale (CIRS), 15, 16 which assesses the severity of coexisting diseases in 14 organ systems/scales, scored from 0 to 4.
CIRS-G (CIRS revised and validated to reflect common geriatric
problems) including the presence of eight specific geriatric syndromes at diagnosis: dementia, delirium, depression, osteoporosis, incontinence, falls, failure to thrive, and neglect/abuse. [17] [18] [19] [20] This reflected the loss of activities of daily living (ADLs): loss in the ability to undertake the activities of bathing, dressing, toileting, transferring, feeding, and/or maintaining continence. Patients were classified as "fit" if they had no loss of ADLs, less than three grade 3 CIRS-G comorbidities, no grade 4 CIRS-G, and did not have a geriatric syndrome at the time of initial diagnosis, or "unfit"
if any of these were present. 21, 22 3. Charlson Comorbidity Index (CCI). 23 This scoring system classifies comorbidities such as heart, lung, and liver diseases, diabetes, cerebrovascular disease, and cancer using a weighted system. A high comorbidity was defined as CCI 2. 
| Centralized histopathogical review
| RE S U L TS
| Patient characteristics
Two-hundred fifty-two patients were included in this analysis. Their main characteristics and the treatment they received are summarized in Table 1 . The median age was 83 years (range, 80-100 years) and 59 patients (23%) were older than 85 years. Histology was consistent with DLBCL in 95% of patients. 160 patients (63%) were treated with chemotherapy including anthracyclines and/or rituximab, whereas 37 patients (15%) did not receive any chemotherapeutic treatment and 19 patients (7.5%) did not receive any treatment at all.
| Survival analysis in the overall series
With a median follow-up of 44 months (range, 12-142 months), median PFS and OS in the overall series were 9.5 and 12.5 months, respectively (27% and 34% at 3 years) (Supporting Information Figure   S1 ). In the univariate analyzes (Supporting Information Table S1 ), age 86 years, CIRS 6, being "unfit," CCI 2, high-risk R-IPI, no rituximab treatment and no anthracycline treatment were significantly associated with worse PFS and OS. In the multivariate analysis, age < 86, CIRS < 6, intermediate-risk R-IPI and rituximab treatment remained independent risk factors predicting better OS and PFS, as shown in Supporting Information Table S2 .
| Analysis restricted to patients treated with chemotherapy
We performed an analysis restricted to patients treated with chemo- Table 2 . Patients receiving anthracycline-containing treatments (CHOP or R-CHOP) were younger than those receiving R-CVP or palliative treatment. Significantly more patients in the CHOP group had a high-risk R-IPI (P 5 .021). Comorbidity indexes were not apparently of value in the choice of treatment type ( Table 2 ).
The median number of cycles administered was 5 and 6 in the R-CHOP and R-CHOPr groups, respectively, significantly higher than the median of cycles administered in the R-CVP and CHOP groups (3 and 4, respectively) ( Table 2) . CR and OR rates were significantly better in patients receiving R-CHOP and R-CHOPr, as shown in Table 2 .
Treatment-related mortality was lower in the R-CHOPr and palliative groups, although the difference from the other groups was not statistically significant. However, lymphoma-related mortality was significantly lower in patients treated with rituximab-containing regimens (R-CHOP, R-CHOPr, or R-CVP) ( Table 2) .
PFS and OS Kaplan-Meier curves are shown in Figure 1 . PFS and OS were significantly better in the R-CHOP (median of 28 and 40 months, respectively) and R-CHOPr groups (19 and 24 months) than in the R-CVP (7 and 12 months), CHOP (6 and 7 months), and palliative (4 and 6 months) groups (P < .001). Other factors significantly affecting PFS or OS in univariate analysis are shown in Supporting Information Table S3 . In the multivariate analysis of PFS and OS, treatment with R-CHOP and R-CHOPr maintained the statistical significance, independently of age, CIRS and R-IPI, as shown in Table 3 . 
| Prognostic factors of OS in patients treated with R-CHOP
Finally, as the best results were observed in patients treated with R-CHOP and R-CHOPr, we performed a subanalysis of this group (108 patients). In the univariate analyzes of PFS and OS, age< 86 years, CIRS < 6, "fit" patients, CCI < 2 and R-IPI intermediate-risk were associated with better PFS and OS. In the multivariate analysis only age, CIRS and R-IPI were independent prognostic factors of OS. Based on this, a prognostic score was obtained, which revealed two groups with significantly different OS (Supporting Information Figure S2 ): 3-year OS and PFS were 58% and 50% (median, 45 and 35 months) vs. 25% and 22% (median, 12 and 10 months) (P 5 .001), respectively, in patients with 0-1 vs. 2-3 risk factors.
| Centralized histopathological review
CD20 was expressed in all samples from the 53 cases with sufficient material available for a complete IHC workup. The samples were divided into GCB (33 cases, 62%) and non-GCB (20 cases, 38%) based on the Hans algorithm. 13 cases (15%) were double-positive for MYC and BCL2 and no association with the GCB or non-GCB phenotypes was found (P 5 .819). In 9 cases (17%) CD301 cells were identified in at least 5% of the neoplastic infiltrate. This prevalence is consistent with previously published results from a large retrospective series. 25 PDL-1 (using clone 22C3) was positive in 6 cases (11%) with no apparent association with EBV infection (none of these cases was EBV positive). It is likely that genetic alterations at the 9q24 locus are related with PDL1 overexpression, in the absence of EBV infection in the tumoral cells. 26 The low prevalence of EBV1 large B-cell lymphoma in this series of very elderly patients should also be noted. We found a single case (2%) of EBV 1 DLBCL, which is consistent with its prevalence in western populations. 27 
| D ISC USSION
In the present study, we have analyzed a large series of patients aged at least 80 years with aggressive B-cell lymphoma treated between 2002 and 2014 in 19 hospitals from the GELTAMO group. Strikingly, only 43% of patients received standard treatment with R-CHOP at full or reduced doses, while the remaining patients received a variety of less intense regimens (15% without any chemotherapeutic agent), and 7.5% received no treatment whatsever. These data reflect two facts already described in other studies 7, 8, 12 : (i) it is highly likely that very elderly patients with DLBCL will not receive treatment with curative intent; and (ii) there is no standard treatment for patients considered to be frail, i.e., those whose treating physician believes them incapable of tolerating a regimen with curative intent.
In our study, patients treated with R-CHOP at full or reduced doses had good results in terms of OS (median, 40 and 24 months, respectively), significantly better than those receiving R-CVP (12 months), CHOP (7 months) or palliative treatment (6 months). These results are in agreement with those of other groups, 8, 9 and indicate that, as in younger patients in whom randomized studies have been conducted, R-CHOP or similar is also the treatment of choice for patients over 80 years old who can tolerate it. CCI, Charlson comorbidity index; CIRS, cumulative illness rating scale; Palliative, includes cyclophosphamide 1/-prednisone 1/-vincristine; R-CHOP, rituximab, cyclophosphamide, adriamycin, vincristine, prednisone; R-CHOPr: R-CHOP with any type of dose reduction; R-CVP: rituximab, cyclophosphamide, vincristine, prednisone.
In a prospective phase 2 trial, Peyrade et al. 11 investigated the Rmini-CHOP regimen in 149 patients with DLBCL who were more than 80 years of age. This trial confirmed the feasibility and efficacy (49% OS at 4 years) of this reduced R-CHOP in very old patients, and, since then, R-mini-CHOP has become the preferred regimen in many centers for patients over 80 years old. In our study, the best survival results were observed in patients treated with full-dose R-CHOP, but these had higher treatment-related mortality than patients treated with reduced doses. The small numbers of patients in our series who received reduced-dose R-CHOP prevented us reaching firm conclusions about the dose intensity of R-CHOP and its outcomes.
Another finding of our study is the survival benefit to patients receiving rituximab, which proved to be an independent prognostic factor in the multivariate analyzes of PFS and OS in the global series. This is an important finding because published prospective randomized studies comparing R-CHOP with CHOP are limited to patients in the age range of 60-80 years, and there are no published randomized studies demonstrating the benefit of administering rituximab to patients older than 80 years.
11
Conversely, the presence of comorbidities was a key prognostic factor of survival in our study, although the comorbidity scales did not seem to influence the choice of treatment type (curative or palliative)
significantly, as shown in Table 2 . All the comorbidity scales analyzed hemato-oncologists may also be necessary to better evaluate the fitness of these patients.
In our study, we created a prognostic model based on multivariate analysis of the 108 patients treated with the R-CHOP-like regimen.
Patients 
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